[Federal Register Volume 66, Number 94 (Tuesday, May 15, 2001)]
[Notices]
[Pages 26871-26872]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-12126]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

[[Page 26872]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Discovery of Proteins That Are Aberrantly Expressed in Laser 
Capture Microdissected Human Solid Tumors

Emmanuel Petricoin (FDA), Lance Liotta (NCI), Michael Emmert-Buck 
(NCI), Yingming Zhao (EM)
DHHS Reference No. E-083-01/0 filed 01 February 2001
Licensing Contact: Matthew Kiser; 301/496-7735 ext. 224; e-mail: 
<a href="/cdn-cgi/l/email-protection#1f74766c7a6d725f707b3171767731787069"><span class="__cf_email__" data-cfemail="63080a1006110e230c074d0d0a0b4d040c15">[email protected]</span></a>

    The post-genomic era has created a need for a direct method to 
monitor the levels of expressed proteins in developing, diseased or 
genetically altered tissues. Direct monitoring of tissue has proven 
difficult because of the heterologous, three-dimensional structure. 
Prior methods for extracting and analyzing biomolecules from tissue 
subpopulations were complicated, labor intensive, and did not utilize 
protein stabilizers. There has been no way to directly compare, without 
the danger of cross-contamination, the spectrum of proteins contained 
in normal cells with the proteins in tumor cells in a single tissue. 
Many of the hypotheses regarding altered protein levels in tumor cells 
have been based on work on cell lines and their viability in culture 
media. The amount and type of protein expressed by cells in the native 
tissue environment can be quite different than that of cultured cells. 
Thus, the need exists for a direct means of measuring protein levels to 
obtain results reflecting in vivo conditions. This technology supplies 
the means to obtain in vivo expression levels.
    The present invention describes devices and methods for performing 
protein analysis on laser capture microdissected cells, which 
facilitate proteomic analysis on cells of different populations. The 
protein content can be determined by any of the standard analytical 
techniques: immunoassays, 1D and 2D electrophoresis, Western blotting, 
LCQ-MS, MALDI/TOF, and SELDI. Specific applications include, but are 
not limited to, analysis of normal versus malignant cells, differential 
expression determination of cellular proteins at various disease states 
(e.g. normal, pre-malignant, tumor), and comparison of expression 
levels of different types of cancers (e.g. esophageal, prostate, 
breast, ovarian, lung, and colon cancer).
    A second embodiment of this technology provides specific examples 
of tumor or tumor-stage linked protein ``fingerprints'' and specific 
proteins identified from these ``fingerprints'' as being aberrantly 
expressed in specific diseased cell types. Furthermore, methods of 
using these ``fingerprints'', sub-sets thereof, and individual proteins 
in the diagnosis, prognosis, treatment, treatment selection, and drug 
development for disease are provided.

Production and Use of Anti-Dorsalizing Morphogenetic Protein

M. Moos Jr., M. Krinks, S. Wang (FDA)
Serial No. 08/335,583 filed 08 Nov 1994, now US Patent 5,693,779 issued 
02 Dec 1997
Licensing Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail: 
<a href="/cdn-cgi/l/email-protection#c2b0b7a1a9a7b0b182ada6ecacabaaeca5adb4"><span class="__cf_email__" data-cfemail="1e6c6b7d757b6c6d5e717a3070777630797168">[email protected]</span></a>

    This patent relates to the identification, isolation and cloning of 
the cDNA which encodes a protein, Anti-Dorsalizing Morphogenetic 
Protein-1 (ADMP-1). ADMP-1 is related to the bone morphogenetic 
proteins and is a member of the TGF beta superfamily. ADMP-1 is 
involved in the down-regulation of multiple factors related to tissue 
proliferation and may be useful in inhibiting inappropriate tissue 
proliferation such as that associated with psoriasis or melanoma.
    This work has been published, in part, at Moos, M, et al. ``Anti-
dorsalizing morphogenetic protein is a novel TGF-beta homolog expressed 
in the Spemann organizer'' Development 121(12):4293-301 (Dec 1995).

    Dated: May 7, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-12126 Filed 5-14-01; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>